Codexis (NASDAQ:CDXS) versus Liquidia (NASDAQ:LQDA) Head-To-Head Comparison

Codexis (NASDAQ:CDXS) and Liquidia (NASDAQ:LQDA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Valuation & Earnings

This table compares Codexis and Liquidia”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39 million	3.62	-$43.97 million	($0.37)	-7.57
Liquidia	$288.07 million	19.24	-$68.92 million	$0.14	445.17

Codexis has higher earnings, but lower revenue than Liquidia. Codexis is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

78.5% of Codexis shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 3.5% of Codexis shares are owned by insiders. Comparatively, 25.6% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Codexis and Liquidia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Codexis	-40.97%	-68.09%	-23.72%
Liquidia	7.74%	46.82%	7.06%

Analyst Recommendations

This is a summary of recent ratings and target prices for Codexis and Liquidia, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1	0	1	0	2.00
Liquidia	2	0	6	3	2.91

Codexis presently has a consensus price target of $5.00, indicating a potential upside of 78.57%. Liquidia has a consensus price target of $53.50, indicating a potential downside of 14.16%. Given Codexis’ higher probable upside, research analysts plainly believe Codexis is more favorable than Liquidia.

Risk and Volatility

Codexis has a beta of 2.48, meaning that its stock price is 148% more volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.

Summary

Liquidia beats Codexis on 11 of the 15 factors compared between the two stocks.

About Codexis

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.